

Special Issue

Advances in Cancer Vaccines: From Bench to Bedside

Message from the Guest Editors

This Special Issue will cover the latest progress in cancer vaccine research and developments. We aim to provide a comprehensive overview of recent developments in cancer vaccines, including novel targets, formulations, and delivery systems.

Furthermore, we intend to explore the potential of combination therapies that incorporate cancer vaccines and the identification of biomarkers to guide patient selection and monitoring. Additionally, the Special Issue will cover the research on mRNA-based cancer vaccines, which represent a promising new approach to cancer immunotherapy due to their flexibility and speed of development. This Special Issue will be of immense interest to researchers, clinicians, and policymakers involved in cancer immunotherapy, and it is hoped that it will make a significant contribution to the field of cancer therapy, and have a positive impact on patient outcomes. We invite submissions of original research articles, reviews, and perspectives that provide insights into cancer vaccine development, immune correlates of protection, regulatory and ethical considerations, and other relevant topics. We look forward to your contributions and collaboration.

Guest Editors

Prof. Dr. Qizhi Cathy Yao

Dr. Alok K. Mishra

Dr. Sunil K. Malonia

Deadline for manuscript submissions

closed (31 July 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/172029

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).